Cargando…
Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247494/ https://www.ncbi.nlm.nih.gov/pubmed/34016610 http://dx.doi.org/10.2337/dci21-0009 |
| _version_ | 1783716535016095744 |
|---|---|
| author | Neeland, Ian J. Kasai, Takatoshi Inzucchi, Silvio E. Wojeck, Brian S. Yaggi, Henry K. Johansen, Odd Erik |
| author_facet | Neeland, Ian J. Kasai, Takatoshi Inzucchi, Silvio E. Wojeck, Brian S. Yaggi, Henry K. Johansen, Odd Erik |
| author_sort | Neeland, Ian J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8247494 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82474942022-06-01 Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015 Neeland, Ian J. Kasai, Takatoshi Inzucchi, Silvio E. Wojeck, Brian S. Yaggi, Henry K. Johansen, Odd Erik Diabetes Care e-Letters: Comments and Responses American Diabetes Association 2021-06 2021-06-18 /pmc/articles/PMC8247494/ /pubmed/34016610 http://dx.doi.org/10.2337/dci21-0009 Text en © 2021 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license. |
| spellingShingle | e-Letters: Comments and Responses Neeland, Ian J. Kasai, Takatoshi Inzucchi, Silvio E. Wojeck, Brian S. Yaggi, Henry K. Johansen, Odd Erik Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015 |
| title | Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015 |
| title_full | Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015 |
| title_fullStr | Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015 |
| title_full_unstemmed | Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015 |
| title_short | Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015 |
| title_sort | response to comment on neeland et al. the impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes: an exploratory analysis of the empa-reg outcome trial. diabetes care 2020;43:3007–3015 |
| topic | e-Letters: Comments and Responses |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247494/ https://www.ncbi.nlm.nih.gov/pubmed/34016610 http://dx.doi.org/10.2337/dci21-0009 |
| work_keys_str_mv | AT neelandianj responsetocommentonneelandetaltheimpactofempagliflozinonobstructivesleepapneaandcardiovascularandrenaloutcomesanexploratoryanalysisoftheemparegoutcometrialdiabetescare20204330073015 AT kasaitakatoshi responsetocommentonneelandetaltheimpactofempagliflozinonobstructivesleepapneaandcardiovascularandrenaloutcomesanexploratoryanalysisoftheemparegoutcometrialdiabetescare20204330073015 AT inzucchisilvioe responsetocommentonneelandetaltheimpactofempagliflozinonobstructivesleepapneaandcardiovascularandrenaloutcomesanexploratoryanalysisoftheemparegoutcometrialdiabetescare20204330073015 AT wojeckbrians responsetocommentonneelandetaltheimpactofempagliflozinonobstructivesleepapneaandcardiovascularandrenaloutcomesanexploratoryanalysisoftheemparegoutcometrialdiabetescare20204330073015 AT yaggihenryk responsetocommentonneelandetaltheimpactofempagliflozinonobstructivesleepapneaandcardiovascularandrenaloutcomesanexploratoryanalysisoftheemparegoutcometrialdiabetescare20204330073015 AT johansenodderik responsetocommentonneelandetaltheimpactofempagliflozinonobstructivesleepapneaandcardiovascularandrenaloutcomesanexploratoryanalysisoftheemparegoutcometrialdiabetescare20204330073015 |